Shanghai Yizhong Pharmaceutical Co., Ltd. (SHA:688091)

Market Cap	8.02B -38.7%
Revenue (ttm)	321.61M +51.8%
Net Income	68.86M +557.6%
EPS	0.34 +710.0%
Shares Out	204.80M
PE Ratio	114.81
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,050,244
Open	39.38
Previous Close	39.15
Day's Range	38.39 - 39.42
52-Week Range	35.28 - 66.20
Beta	-0.44
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 26, 2026

About SHA:688091

Shanghai Yizhong Pharmaceutical Co., Ltd. engages in the research and development of anti-tumor drugs and related products in China. The company offers paclitaxel polymer micelles for injection for the treatment of non-small cell lung cancer, as well as various types of cancer, including esophageal cancer, gastric cancer, nasopharyngeal carcinoma, pancreatic cancer, breast cancer, and gynecological tumors. Shanghai Yizhong Pharmaceutical Co., Ltd. was founded in 2009 and is headquartered in Shanghai, China.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2009
• Employees: 437
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688091

Financial Performance

In 2025, SHA:688091's revenue was 316.08 million, an increase of 82.14% compared to the previous year's 173.53 million. Earnings were 64.56 million, an increase of 825.49%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 10, 2026

Data Sources Report a data error